Eli Lilly paused trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Companyメs…
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
On Oct. 9, 2020, Rigel Pharma announced enrollment of the first patients in a multicenter, Phase 2 trial…
On Oct. 9, 2020, OPKO Health subsidiary BioReference Labs, New York City, the Department of Health, New York…
On Oct. 9, 2020, Pfizer and BioNTech announced the initiation of a rolling submission to Health Canada for…
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
On Oct. 8, 2020, the National Cancer Institute (NCI) launched the Serological Sciences Network for COVID-19 (SeroNet), an…
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
On Oct. 8, 2020, bioMerieux and the Africa Medical Supplies Platform (AMSP), announced a new partnership to facilitate…
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
On Oct. 8, 2020, Gilead Sciences and the European Commission signed a joint procurement agreement (JPA) that enabled…
On Oct. 8, 2020, The New England Journal of Medicine (NEJM) published the final results from the National…
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
On Oct. 8, 2020, Eli Lilly and Incyte shared additional data showing baricitinib in combination with remdesivir reduced…
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
On Oct. 8, 2020, the National Institutes of Health (NIH) awarded a Research Project Cooperative Agreement grant to…
On Oct. 8, 2020, Johnson & Johnson announced the European Commission, acting on behalf of the European Union…
On Oct. 8, 2020, Caladrius Biosciences announced that it had opened its proof-of-concept study of CLBS119 as a…
On Oct. 7, 2020, in a continuing effort to provide the facts about ID NOW to support public…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Oct. 7, 2020, Mateon Therapeutics announced the first patient enrolled this week in its Phase IV study…
On Oct. 7, 2020, Kindred Biosciences announced it had expanded an agreement with Vaxart for the manufacture of…
On Oct. 7, 2020, Eli Lilly announced additional details on its SARS-CoV-2 neutralizing antibody programs ヨ including interim…
On Oct. 7, 2020, Sonic Healthcare USA announced that it had launched a multiplex RT-PCR assay that combined…
On Oct. 6, 2020, the National Institutes of Health (NIH), working in collaboration with the Biomedical Advanced Research…
On Oct. 6, 2020, Hologic announced that its Aptimaᆴ SARS-CoV-2 assay, which initially received Emergency Use Authorization (EUA)…